Repository logo
 
Publication

The role of iron related gene variants in liver disease severity and iron metabolism parameters in chronic hepatitis C patients treated with direct-acting antivirals

dc.contributor.authorFerreira, Joana
dc.contributor.authorBicho, Manuel
dc.contributor.authorSerejo, Fátima
dc.contributor.authorFaustino, Paula
dc.date.accessioned2020-05-21T10:55:45Z
dc.date.available2020-05-21T10:55:45Z
dc.date.issued2019-05
dc.description.abstractChronic hepatitis C (CHC) is usually associated with iron overload, which may modulate the severity of liver disease. Direct-acting antivirals (DAAs) have made HCV treatment faster and more efficient. However, little is known about their effect on liver disease severity and iron metabolism disruption. This study aimed to evaluate the role of iron related gene variants in liver disease severity and iron status associated parameters in CHC patients treated with DAAs. A group of 118 out of 255 CHC patients (49±12 years) was treated with DAAs and clinical evaluation was performed after 3 to 6 months. Liver fibrosis stage was assessed by FibroScan and the following iron status parameters were evaluated: serum iron (Fe), ferritin (FT), transferrin (TF), transferrin saturation (TFS) and haptoglobin (Hp). HFE common variants (H63D and C282Y) were analysed by PCR-RFLP and the TF_rs3811647 by Sanger sequencing. Statistical analysis was performed using SPSS 23.0. Before DAAs treatment, patients with higher fibrosis stage (F3/4) showed significantly higher Fe, FT and TF, and lower Hp (p=0.030; p=0.026; p=0.025; p=0.048). We found higher Fe, TFS and FT in patients HFE_CY or YY (p=0.008; p=0.003; p=0.002) and higher TF in patients TF_rs3811647_GA or AA (p=0.029). After DAAs treatment, patients presented: i) an improvement of liver fibrosis showed by a higher frequency of patients with lower fibrosis stage (F1/2) (p<0.001); and ii) an improvement of iron status revealed by lower Fe, TFS and FT (p=0.007; p=0.048; p<0.001) and higher Hp (p=0.001). We observed that only in patients HFE_CC and HFE_HD or DD, TF decreased after treatment (p=0.028; p=0.012). In these same patients and in those TF_rs3811647_GG or GA, Hp increased (p=0.003; p=0.006) after antiviral treatment. Specific genetic variants in iron related genes may have a relevant role in the predisposition for severe liver disease in CHC patients before DAAs treatment, and in the improvement of iron status after HCV clearance.pt_PT
dc.description.sponsorshipFCT PDE/BDE/114585/2016 and CENCpt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.urihttp://hdl.handle.net/10400.18/6732
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/pt_PT
dc.subjectChronic Hepatitis Cpt_PT
dc.subjectIron Metabolismpt_PT
dc.subjectDirect-acting Antiviralspt_PT
dc.subjectHepatite Cpt_PT
dc.subjectDoenças Genéticaspt_PT
dc.subjectMetabolismo do Ferropt_PT
dc.titleThe role of iron related gene variants in liver disease severity and iron metabolism parameters in chronic hepatitis C patients treated with direct-acting antiviralspt_PT
dc.typeconference object
dspace.entity.typePublication
oaire.citation.conferencePlaceHeidelberg, Germanypt_PT
oaire.citation.title8th Congress of the International BioIron Society. European Molecular Biology Laboratory, 5-10 May 2019pt_PT
person.familyNameFaustino
person.givenNamePaula
person.identifier.ciencia-idF01A-353A-433E
person.identifier.orcid0000-0002-6269-4867
person.identifier.ridM-3519-2014
person.identifier.scopus-author-id8158641100
rcaap.rightsopenAccesspt_PT
rcaap.typeconferenceObjectpt_PT
relation.isAuthorOfPublication94303e78-8b7d-4e24-811d-3af3b1a4e330
relation.isAuthorOfPublication.latestForDiscovery94303e78-8b7d-4e24-811d-3af3b1a4e330

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Poster BIOIRON 2019_final abril 2019 PDF.pdf
Size:
3 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: